Abeona Therapeutics Inc
PCJ
Company Profile
Business description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136
Stocks News & Analysis
stocks
More US tech stocks look cheap as the market rotates
Meanwhile, value-leaning areas of the market, including industrials and energy stocks, are moving out of undervalued territory.
stocks
Earnings Losers: GYG, DMP & LLC slump on souring market sentiment
The results that fell short of market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,430.60 | 80.60 | 0.86% |
| CAC 40 | 8,412.12 | 168.63 | -1.97% |
| DAX 40 | 24,729.29 | 554.97 | -2.19% |
| Dow JONES (US) | 48,977.92 | 521.28 | -1.05% |
| FTSE 100 | 10,788.57 | 121.98 | -1.12% |
| HKSE | 26,059.85 | 570.69 | -2.14% |
| NASDAQ | 22,668.21 | 210.17 | -0.92% |
| Nikkei 225 | 58,057.24 | 793.03 | -1.35% |
| NZX 50 Index | 13,656.65 | 66.32 | -0.48% |
| S&P 500 | 6,878.88 | 29.98 | -0.43% |
| S&P/ASX 200 | 9,200.90 | 81.20 | 0.89% |
| SSE Composite Index | 4,182.59 | 19.71 | 0.47% |